Keros Q2 net loss $37.5M, cash $322M; plans KER-065 Phase 1 in DMD for Q1 2024

Keros Therapeutics, Inc.

2023-Q2 EPS reported -$2.53

Net loss of $37.5M in Q2 2023 vs $27.3M in Q2 2022, driven by increased R&D spend.
R&D expenses $32.5M (+$9.3M YoY) on pipeline advancement and manufacturing.
Cash and equivalents $322.0M as of June 30, 2023; expects runway into Q4 2025.
Phase 2 TROPOS trial of KER-012 in PAH cleared by FDA; webcast on trial design Aug 8.
KER-065 for Duchenne muscular dystrophy to start Phase 1 in healthy volunteers Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Keros Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income a net loss of $37.5 million.

Period: the quarter ended June 30, 2023
Net income: a net loss of $37.5 million
Result: reported results

Exact text from the filing

Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-23-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.